Company intelligence / Profile preview

Immutep S.A.S.

Sydney, New South Wales, Australia

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Immutep’s lead candidate, eftilagimod alpha (efti), is in a pivotal Phase 3 trial in first-line non-small cell lung cancer in combination with pembrolizumab and chemotherapy; multiple Phase 2 and earlier trials in various solid tumors and autoimmune diseases are ongoing. The company has licensed out certain LAG-3 pipeline assets to major pharma partners with external programs in both oncology and autoimmune diseases. Efti has shown improved response rates and robust safety in several completed and ongoing studies.[1][4][2]

Therapeutic areas: OncologyImmunology
Modalities: Recombinant fusion proteinMonoclonal antibody
Industry: Biotech

Partnerships

NovartisGlaxoSmithKlineEOC Pharma

Beyond the preview

Go deeper on Immutep S.A.S..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immutep S.A.S..

Explore the full profile